Spero Therapeutics
(NASDAQ:SPRO)
$1.94
0.01[0.52%]
At close: Nov 30(Delayed 15-Minutes)
Get Real Time Here
$1.92
-0.0200[-1.03%]
After Hours: 4:59PM EDT
Day Range1.9 - 1.9652 Wk Range0.68 - 16.3Open / Close1.91 / 1.94Float / Outstanding46.5M / 51.8M
Vol / Avg.296K / 7.9MMkt Cap100.4MP/E-50d Avg. Price1.91
Div / Yield-Payout Ratio-Total Float46.5MEPS-0.33

Spero Therapeutics Stock (NASDAQ:SPRO), Quotes and News Summary

Spero Therapeutics Stock (NASDAQ: SPRO) stock price, news, charts, stock research, profile.

Loading...
Day Range1.9 - 1.9652 Wk Range0.68 - 16.3Open / Close1.91 / 1.94Float / Outstanding46.5M / 51.8M
Vol / Avg.296K / 7.9MMkt Cap100.4MP/E-50d Avg. Price1.91
Div / Yield-Payout Ratio-Total Float46.5MEPS-0.33
Christopher Sappo - Sep 23, 2022, 10:35AM
Globe Newswire - Oct 19, 2022, 8:05AM
InvestorsObserver - Nov 22, 2022, 7:28AM
InvestorsObserver - Nov 16, 2022, 6:31AM
InvestorsObserver - Nov 15, 2022, 12:17PM
InvestorsObserver - Nov 8, 2022, 8:10AM
InvestorsObserver - Nov 2, 2022, 8:27AM
InvestorsObserver - Oct 24, 2022, 11:24AM
InvestorsObserver - Oct 13, 2022, 7:02AM
Sector: Health Care.Industry: Biotechnology
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Earnings

see more
Q3 2022Est.ActualSurprise
EPS-0.300-0.330 -0.0300
REV5.420M2.006M-3.414M
Q2 2022Est.ActualSurprise
EPS-0.540-0.510 0.0300
REV1.150M1.993M843.000K

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Spero Therapeutics (SPRO) stock?

A

You can purchase shares of Spero Therapeutics (NASDAQ: SPRO) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Spero Therapeutics's (SPRO) competitors?

Q

What is the target price for Spero Therapeutics (SPRO) stock?

A

The latest price target for Spero Therapeutics (NASDAQ: SPRO) was reported by HC Wainwright & Co. on Monday, September 26, 2022. The analyst firm set a price target for 6.00 expecting SPRO to rise to within 12 months (a possible 209.28% upside). 10 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Spero Therapeutics (SPRO)?

A

The stock price for Spero Therapeutics (NASDAQ: SPRO) is $1.94 last updated Today at November 30, 2022, 9:00 PM UTC.

Q

Does Spero Therapeutics (SPRO) pay a dividend?

A

A quarterly cash dividend of $0.01 per share of Class A Common Stock. The quarterly cash dividend was payable on October 7, 2015 to stockholders of record on September 16, 2015.

Q

When is Spero Therapeutics (NASDAQ:SPRO) reporting earnings?

A

Spero Therapeutics’s Q3 earnings are confirmed for Monday, November 14, 2022.

Q

Is Spero Therapeutics (SPRO) going to split?

A

There is no upcoming split for Spero Therapeutics.

Q

What sector and industry does Spero Therapeutics (SPRO) operate in?

A

Spero Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.